When the FDA considers switching a prescription to an OTC product, which questions are evaluated?

When the FDA considers switching a prescription to an OTC product, which questions are evaluated?

• A. Can patient self-diagnose the problem?
• B. Can the problem be treated?
• C. Is the product safe and effective for consumer use?
• D. All three questions must be affirmative

Answer: (D)

When the FDA contemplates moving a prescription drug to OTC, it weighs whether a consumer can safely handle the product without professional supervision. The decision hinges on three things working together: first, can a consumer reasonably identify the condition the product is meant to treat? second, can the consumer recognize that the product is intended for that problem and know it can provide relief or benefit? third, is the product safe and effective for use by consumers when following the label directions? If any of these aspects isn’t clearly satisfied—if the condition isn’t something a typical consumer can accurately diagnose, or if the product wouldn’t reliably help, or if its safe use by the general public can’t be assured with labeling—then the switch to OTC isn’t appropriate. That’s why all three questions must be affirmatively addressed, making option that encompasses all three the best choice.

When the FDA contemplates moving a prescription drug to OTC, it weighs whether a consumer can safely handle the product without professional supervision. The decision hinges on three things working together: first, can a consumer reasonably identify the condition the product is meant to treat? second, can the consumer recognize that the product is intended for that problem and know it can provide relief or benefit? third, is the product safe and effective for use by consumers when following the label directions?

If any of these aspects isn’t clearly satisfied—if the condition isn’t something a typical consumer can accurately diagnose, or if the product wouldn’t reliably help, or if its safe use by the general public can’t be assured with labeling—then the switch to OTC isn’t appropriate. That’s why all three questions must be affirmatively addressed, making option that encompasses all three the best choice.